Merck to Acquire SpringWorks Therapeutics, Expanding Leadership in Rare Tumors and Advancing Healthcare Innovation

(IN BRIEF) Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significantly enhance Merck’s rare tumor portfolio, adding first-in-class therapies for desmoid tumors and NF1-PN. The deal aligns with Merck’s strategy to accelerate growth through innovation, strengthen its U.S. presence, and improve patient outcomes in the rare cancer space. The transaction is expected to close in the second half of 2025.

(PRESS RELEASE) DARMSTADT, 28-Apr-2025 — /EuropaWire/ — Merck (DAX: MRK) has announced an agreement to acquire SpringWorks Therapeutics, a U.S.-based biopharmaceutical company focused on treating severe rare diseases and cancer. This acquisition, valued at approximately $3.9 billion, will enhance Merck’s presence in the rare tumor segment and accelerate its long-term growth strategy within the healthcare sector.

SpringWorks Therapeutics brings an innovative portfolio to Merck, including the first approved systemic therapy for adults with desmoid tumors and the first and only FDA-approved treatment for pediatric and adult patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). This acquisition will significantly strengthen Merck’s healthcare business and contribute to its expansion in the U.S. market.

Merck’s CEO Belén Garijo expressed her enthusiasm for the deal, stating, “The acquisition of SpringWorks aligns with our strategic goal to drive innovation and technology within Merck, particularly focusing on rare tumors. This collaboration will accelerate our growth, enabling us to provide impactful solutions to patients with rare cancers.”

The deal is in line with Merck’s ongoing strategy to pursue high-quality external innovations and focused acquisitions. The integration of SpringWorks’ advanced therapies will contribute to Merck’s efforts to enhance healthcare outcomes and strengthen its position in the rare tumor sector.

The acquisition is expected to close in the second half of 2025, subject to customary regulatory approvals. Merck plans to fund the acquisition with available cash and new debt, while retaining the flexibility to pursue further strategic transactions in the future.

About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company dedicated to improving the lives of patients with severe rare diseases and cancer. We developed and are commercializing OGSIVEO® (nirogacestat) as the first and only FDA-approved medicine for adults with desmoid tumors and GOMEKLI™ (mirdametinib) as the first and only FDA-approved medicine for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN). We are also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers.

For more information, visit www.springworkstx.com and follow @SpringWorksTx on X, LinkedIn,
Facebook, Instagram, and Youtube.

No Solicitation
Merck, its directors and executive officers are not soliciting proxies from the shareholders of SpringWorks in connection with the proposed acquisition and are not participants in the solicitation of proxies by SpringWorks. Merck is making this communication for informational purposes only and does not intend to file any communication relating to the proposed acquisition on a proxy statement on Schedule 14A with the SEC.

Media Contact:

Media Relations:
Gangolf Schrimpf
gangolf.schrimpf@merckgroup.com
Phone: +49 151 1454 9591

Investor Relations:
investor.relations@merckgroup.com
Phone: +49 6151 72-3321

SOURCE: Merck